Neil Mehta of @BrownUniversity and coauthors examine Rhode Island's 2010 affordability standards and find that hospital revenue reductions after price growth caps were implemented in the state resulted in reductions in hospital labor costs and staffing. https://t.co/jWAOKIFZOO
The rapid expansion of autism therapy for children has been driven by increased need, generous taxpayer-funded Medicaid payments, and private equity penetration, leading some companies to capitalize on the opportunity, at times outpacing regulatory oversight. | Forefront
@ysingh_phd, et al. | @Brown_SPH
https://t.co/al6EQ92SKk
Broker enrollment in #MedicareAdvantage plans drove spending increases from $3.9 billion in 2014 to $10.1 billion in 2022, with most payments now attributed to renewal fees. https://t.co/Xp1ssOVdXJ
AI for claims review and prior authorization: Our new brief examines current consumer protections regarding AI’s use in health care — and how the Trump administration’s proposed AI framework could preempt some state’s protections.
🔗: https://t.co/ECdO0Q6GsF
Among traditional #Medicare beneficiaries, private equity acquisition of primary care practices was not associated with changes in all-cause or preventable hospitalizations, but modestly reduced emergency department visits.
https://t.co/XtkUYETTdp
💬 Editorial: Most federal actions against #MedicareAdvantage plans involved low fines, with rare suspensions or terminations, emphasizing the need for improved oversight and a deeper understanding of plan quality and patient impact. https://t.co/xF3j9goZUx
Layoffs in the Information sector (which includes much of tech) jumped in March, to their highest level on record outside the pandemic spike. Notable because the earlier wave of tech layoff announcements really didn't show up in the data.
Most federal enforcement against #MedicareAdvantage plans from 2010–2023 were modest monetary penalties, with suspensions or terminations affecting plans with lower star ratings and more minority or dual-eligible enrollees. https://t.co/yCsXnK85an
New @JAMANetwork study! We document that non-profit hospitals have spent billions on management consultants and estimate the effects of this spending. In short, we find little statistically-discernible evidence of either major benefits or harms. (Some precise 0s, some wide CIs.)
The End-Stage Renal Disease Treatment Choices model by @CMSGov did not meaningfully increase use of home dialysis or kidney transplant among Medicare beneficiaries with #KidneyDisease after nearly 4 years of implementation.
https://t.co/NA94jh714a
“These are unbelievable increases,” an insurance broker said of rising premium costs for Medigap plans, which cover some Medicare payments for consumers. He's been in the business for 49 years.
@Julie_appleby reports ⤵️
https://t.co/Nn2mfDkGW8
Most branded medication prescriptions initially rejected by prior authorization were delayed or denied, with lower approval rates among patients with Medicaid or multiple disease conditions, highlighting barriers to timely access for these populations. https://t.co/ccZnhVjMbR
CMS’s proposed changes to the Medicare Advantage (MA) program have a strong basis in the empirical evidence and would reduce excess spending in MA. | Forefront
David J. Meyers, et al. | @Brown_SPH
https://t.co/J7uT2h5l19
Starting in 2028, hospitals with off-campus sites must bill separately using distinct National Provider Identifier numbers. | Forefront
Jared Perkins, et al. | @Brown_SPH
https://t.co/FYakJ4qlrv
The average American senior’s Medicare premiums last year were about 10% higher, or more than $200 annually, because of alleged overpayments to private Medicare Advantage plans, congressional investigators found. 🔗 https://t.co/dvxkb4ToY8
Disenrollment from an MA plan soon after enrollment may indicate dissatisfaction with plan benefits. @Brown_SPH's Em Balkan & coauthors examine trends of rapid disenrollment from MA & find that disenrollment increased from 3.5% in 2017 to 12.2% in 2022. https://t.co/nO3XDCloQx
State laws prohibiting prior authorization for buprenorphine were not associated with significant changes in 180-day treatment retention among privately insured patients with #OpioidUseDisorder.
https://t.co/JiKzD1E92G
Get excited! MedPAC's March 2026 Report to Congress will be released on Thursday, March 12th at 12:00 PM. The report will be posted on our website here: https://t.co/OESkCH4pUZ
I'm hiring a statistical analyst. Position shared with @Andy_Ryan_dydx at Brown, based at the University of Michigan. We study how payment and delivery reforms in Medicare are reshaping primary care. Co-authorship and mentorship built in. Please share.
https://t.co/lXm1GXodpw